News
- XIENCE™ V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
- New Abbott Study of Investigational Vicodin CR™ Meets Primary Efficacy Endpoints in Phase III Trial
- Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder
Features
|
Abbott Presents New Approach for Treating Attention-Deficit Hyperactivity Disorder Attention-Deficit Hyperactivity Disorder (ADHD), an ailment historically associated with childhood, persists into adulthood in more than two-thirds of cases. While medical treatment can improve the symptoms of ADHD, currently approved treatments often cause undesirable side effects, including increases in heart rate and blood pressure. |
|
Ensure Nutrition Education Network Helps Fight Malnutrition Malnutrition is a growing, global health problem. In Europe and the Middle East, 10 to 78 percent of hospital patients, particularly the elderly, suffer from the condition. The effects of malnutrition include disease complications, weakened immune function, increased morbidity and mortality, decreased quality of life, and increased cost of health care. |
|
Positive Results Published from First Bioabsorbable Drug-Eluting Stent Trial Abbott's bioabsorbable drug-eluting stent demonstrated excellent clinical safety in patients with coronary artery disease, according to results published in The Lancet. Watch an animation demonstrating how the stent works. |
|
FDA Approves Abbott's FreeStyle Navigator Continuous Glucose Monitoring System Our new FreeStyle Navigator system, now approved in the U.S. for people with diabetes, provides minute-by-minute information about glucose that can lead to quick, proactive diabetes management |
